Market Closed -
Nasdaq
01:30:00 08/05/2024 am IST
5-day change
1st Jan Change
9.96
USD
-2.83%
-7.43%
+5.96%
Surrozen, Inc.'s Equity Buyback announced on December 15, 2022, has closed with 1,310,496 shares, for $2.7 million.
The company closed its plan on December 15, 2022.
Surrozen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
11/04
CI
Surrozen Insider Bought Shares Worth $2,999,994, According to a Recent SEC Filing
09/04
MT
Surrozen, Inc. announced that it has received $17.500008 million in funding from The Column Group, LLC, Ra Capital Management, Inc.
04/04
CI
Surrozen Provides Update on the Phase 1A Clinical Trial of SZN-043 in Healthy Volunteers and Patients with Cirrhosis
01/04
CI
Surrozen, Inc. announced that it expects to receive $17.549999 million in funding
01/04
CI
Surrozen, Inc. Appoints Charles Williams to the Concurrent Position of Chief Operating Officer
07/02
CI
Sector Update: Health Care Stocks Softer Late Thursday Afternoon
19/01
MT
Sector Update: Health Care Stocks Weaker Thursday Afternoon
19/01
MT
Surrozen to Stop Inflammatory Bowel Disease Clinical Trial; Shares Fall
18/01
MT
Surrozen, Inc. Provides Corporate Update on Clinical Programs
18/01
CI
Surrozen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
09/11
CI
Surrozen, Inc. Expects to Initiate A Phase 1a Clinical Trials for SZN-043 and SZN-1326 in Moderate to Severe Alcoholic Hepatitis
09/11
CI
Surrozen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
10/23/10
CI
Surrozen, Inc. Announces Management Changes
20/23/20
CI
Surrozen, Inc.(NasdaqCM:SRZN) dropped from Russell Microcap Index
23/23/23
CI
Surrozen, Inc.(NasdaqCM:SRZN) dropped from Russell Microcap Value Index
23/23/23
CI
Surrozen, Inc.(NasdaqCM:SRZN) dropped from Russell 3000E Value Index
23/23/23
CI
Surrozen, Inc.(NasdaqCM:SRZN) dropped from Russell 3000E Index
23/23/23
CI
Surrozen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
11/23/11
CI
Surrozen, Inc. Announces Appointment of Eric Bjerkholt to its Board
05/23/05
CI
Surrozen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
23/23/23
CI
Transcript : Surrozen, Inc., Q4 2022 Earnings Call, Mar 22, 2023
23/23/23
Transcript : Surrozen, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-12-2023 07:30 AM
12/23/12
Top Premarket Decliners
27/22/27
MT
Weaker-Than-Expected Retail Sales, Hawkish Fed Send US Stock Futures Sharply Lower
15/22/15
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Surrozen, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a range of organs and tissues. The Company is developing tissue-specific antibodies designed to engage the bodyâs existing biological repair mechanisms with a current focus on severe liver and eye diseases. Its two lead product candidates include SZN-043 and SZN-413. SZN-043 is the first development candidate using Surrozenâs SWEETS technology. It is developing SZN-043 for severe liver diseases, initially focusing on alcohol-associated hepatitis. It has completed a Phase I a clinical trial in patients with chronic liver disease and healthy volunteers. SZN-413 is a bi-specific antibody targeting Fzd4-mediated Wnt signaling designed using Surrozenâs SWAP technology. SZN-413 is being developed for the treatment of retinal vascular-associated diseases.
More about the company
Last Close Price
9.96
USD
Average target price
33
USD
Spread / Average Target
+231.33%
Consensus
1st Jan change
Capi.
+5.96% 32.79M +21.74% 46.81B -0.97% 41.37B +47.07% 41.29B -3.52% 28.87B +11.12% 26.06B -19.37% 19.13B +31.18% 12.39B -0.04% 12.08B +0.39% 11.96B
Other Biotechnology & Medical Research
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1